Identification | Back Directory | [Name]
Tiludronic acid | [CAS]
89987-06-4 | [Synonyms]
ACPMD C08141 C1-TMBP ME-3737 Tiludronic TILUDRONIC ACID Tilundronic Acid Tiludronic acid disodium Tiludronate disodium salt hydrate (4-Chlorophenylthio)methylenediphosphonic acid [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate | [Molecular Formula]
C7H9ClO6P2S | [MDL Number]
MFCD00867070 | [MOL File]
89987-06-4.mol | [Molecular Weight]
318.61 |
Chemical Properties | Back Directory | [Melting point ]
174-177 °C | [Boiling point ]
600.7±65.0 °C(Predicted) | [density ]
1.82±0.1 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
H2O: >10mg/mL, clear | [form ]
powder | [pka]
pK1 10.85; pK2 6.90; pK3 2.95; pK4 1.30(at 25℃) | [color ]
white to off-white | [Water Solubility ]
H2O: >10mg/mL, clear |
Hazard Information | Back Directory | [Definition]
ChEBI: Tiludronic acid is an organochlorine compound. | [Biological Activity]
Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphataseleading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to tre at Pagetμs disease. | [Veterinary Drugs and Treatments]
Tiludronate disodium (tiludronic acid) is a bisphosphonate bone
resorption inhibitor that is available in some countries for the intravenous
treatment of navicular disease in horses. Treatment earlier
in the course of the disease apparently results in greater efficacy.
For humans, there is an orally administered FDA-approved
product for treating Paget’s disease (osteitis deformans). |
|
Company Name: |
LGM Pharma
|
Tel: |
1-(800)-881-8210 |
Website: |
www.lgmpharma.com |
Company Name: |
Merck KGaA
|
Tel: |
(+86) 21 2033 8288 |
Website: |
http://www.sigmaaldrich.cn |
Company Name: |
Alfa Chemistry
|
Tel: |
+1 (201) 478-8534 |
Website: |
www.alfa-chemistry.com |
Company Name: |
Leancare Ltd.
|
Tel: |
+33 962096793 |
Website: |
www.leancare.co.uk |
|